The Post Partum Depression (Maternal Depression / Postnatal Depression) drugs in development market research report provides comprehensive information on the therapeutics under development for Post Partum Depression (Maternal Depression / Postnatal Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Post Partum Depression (Maternal Depression / Postnatal Depression). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Post Partum Depression (Maternal Depression / Postnatal Depression) and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Post Partum Depression (Maternal Depression / Postnatal Depression) by 11 companies/universities/institutes. The top development phase for Post Partum Depression (Maternal Depression / Postnatal Depression) is phase i with six drugs in that stage. The Post Partum Depression (Maternal Depression / Postnatal Depression) pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Post Partum Depression (Maternal Depression / Postnatal Depression) pipeline products market are: Bio-Pharm Solutions, Brii Biosciences and GABA Therapeutics.
The key targets in the Post Partum Depression (Maternal Depression / Postnatal Depression) pipeline products market include Gamma Aminobutyric Acid Type A Receptor Subunit, 5-Hydroxytryptamine Receptor 2A, and 5-Hydroxytryptamine Receptor 1A.
The key mechanisms of action in the Post Partum Depression (Maternal Depression / Postnatal Depression) pipeline product include Gamma Aminobutyric Acid Type A Receptor Subunit Agonist with five drugs in Phase III. The Post Partum Depression (Maternal Depression / Postnatal Depression) pipeline products include six routes of administration with the top ROA being Oral and one key molecule types in the Post Partum Depression (Maternal Depression / Postnatal Depression) pipeline products market including Small Molecule.
Post Partum Depression (Maternal Depression / Postnatal Depression) overview
Post Partum Depression also known as maternal depression and postnatal depression is a medical condition occurs during the pregnancy or after giving the birth (post-partum). Most common condition is prevalent in 1 in 7 women. Many factors like anxiety during the trimester, psychological factors, social support, lifestyle changes, and hormonal changes can cause this condition. Most of the cases are left untreated because of the stigmas attached to it. Persistent feelings of sadness, fatigue, lack of contact with people, loss of appetite, sleep disturbances, and frightening thoughts are some common symptoms. Cognitive behavioral therapy and anti-depressants are treatment strategies. Selective Serotonin reuptake inhibitors (SSRIs) are the first-choice antidepressants.
For a complete picture of Post Partum Depression (Maternal Depression / Postnatal Depression)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
